

- **Name:** Zev A. Wainberg MD
 - **Current Position & Affiliation:** Professor of Medicine and Surgery, UCLA School of Medicine, Los Angeles, California
 - **Country:** USA
-

• **Educational Background:**

EDUCATION:

B.A.	05/1995
McGill University	
M.Sc.	01/1997
McGill University	
M.D.	05/2000
Sackler School of Medicine, Tel Aviv University	
Internship, Internal Medicine	2000-2001
Montefiore Medical Center	
Albert Einstein College of Medicine	
Residency, Internal Medicine	2001-2003
Montefiore Medical Center	
Albert Einstein College of Medicine	
Fellowship, Hematology/Oncology	2003-2006
David Geffen School of Medicine at UCLA	

• **Professional Experience:**

Health Sciences Clinical Professor	2020-present
Department of Medicine, Department of Surgery	
Co-Director, GI Oncology Program	
Division of Hematology-Oncology	
David Geffen School of Medicine at UCLA	
Medical Director, Pancreas Cancer Research Program	2016-present
David Geffen School of Medicine at UCLA	
Director, Early Phase Clinical Research Program	2012-present
Jonsson Comprehensive Cancer Center (JCCC)	
David Geffen School of Medicine at UCLA	
Medical Director, Colorectal Cancer Center	2011-present
David Geffen School of Medicine at UCLA	
Medical Director, Upper GI Cancer Center	2019-Present

• Professional Organizations:

Member, American Society of Clinical Oncology (ASCO) 2010-present
Clinical Trial Committee and Member, American Association of Cancer Research (AACR) 2010-present
Member, Scientific Review Committee, ASCO Annual Meeting 2010-present
Member, American Medical Association (AMA) 2010-present

• Professional Organizations:

Member, American Society of Clinical Oncology (ASCO) 2010-present
Clinical Trial Committee and Member, American Association of Cancer Research (AACR) 2010-present
Member, Scientific Review Committee, ASCO Annual Meeting 2010-present
Member, American Medical Association (AMA) 2010-present

• Main Scientific Publications:

Wainberg ZA, Singh AS, Konecny GE, McCann KE, Hecht JR, Goldman J, Chmielowski B, Finn RS, O'Brien N, von Euw E, Price MM, Martinez D, Yonemoto L, Brennan M, Glaspy JA, Slamon DJ.

Preclinical and clinical trial results using Talazoparib and Low-Dose Chemotherapy. Clin Cancer Res. Clin Cancer Res. 2023 Jan 4;29(1):40-49. doi: 10.1158/1078-0432.CCR-22-1553.

Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, Shukui Qin, Kensei Yamaguchi, In-Ho Kim, Anwaar Saeed, Sang Cheul Oh, Jin Li, Haci Mehmet Turk, Alexandra Teixeira, Christophe Borg, Erika Hitre, Adrian A Udrea, Giovanni Gerardo Cardellino, Raquel Guardado Sanchez, Helen Collins, Siddhartha Mitra, Yingsi Yang, Daniel V T Catenacci, Keun-Wook Lee. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Nov;23(11):1430-**Wainberg ZA**, Xie J, Valderrama A, Yin L, Zhang S, Shih CS, Bhagia P, Gu Q, Shitara K, Janjigian YY, Tabernero. Event-free survival as a surrogate for overall survival in gastric and gastroesophageal junction adenocarcinoma: A meta-analysis in the neoadjuvant ±adjuvant setting. Clin Cancer Res. 2023 Jan 18;CCR-22-2920. doi: 10.1158/1078-0432.CCR-22-2920. Online ahead of print.PMID: 36652563